- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare LIC MF Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 1.0 | 5.0 |
Min SIP Amount | ₹200 | ₹100 |
Expense Ratio | 2.44 | 1.92 |
NAV | ₹29.84 | ₹38.83 |
Fund Started | 08 Feb 2019 | 25 Jun 2018 |
Fund Size | ₹84.15 Cr | ₹5044.63 Cr |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
1.0
5.0
Min SIP Amount
₹200
₹100
Expense Ratio
2.44
1.92
NAV
₹29.84
₹38.83
Fund Started
08 Feb 2019
25 Jun 2018
Fund Size
₹84.15 Cr
₹5044.63 Cr
Exit Load
Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 41.12% | 45.80% |
3 Year | 17.72% | 25.04% |
5 Year | 23.11% | 30.41% |
1 Year
41.12%
45.80%
3 Year
17.72%
25.04%
5 Year
23.11%
30.41%
Holding Analysis
Equity | 95.82% | 97.27% |
Cash | 4.18% | 2.73% |
Equity
95.82%
97.27%
Cash
4.18%
2.73%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.87% |
Piramal Pharma Ltd. | 7.26% |
Artemis Medicare Services Ltd. | 6.66% |
Torrent Pharmaceuticals Ltd. | 5.35% |
Syngene International Ltd. | 4.54% |
Glenmark Pharmaceuticals Ltd. | 4.47% |
Mankind Pharma Ltd. | 4.32% |
Neuland Laboratories Ltd. | 4.24% |
Cipla Ltd. | 4.19% |
Suven Pharmaceuticals Ltd. | 4.08% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.77% |
Dr. Reddy's Laboratories Ltd. | 8.48% |
Cipla Ltd. | 7.94% |
Aurobindo Pharma Ltd. | 5.04% |
Gland Pharma Ltd. | 4.38% |
Lupin Ltd. | 4.29% |
Alkem Laboratories Ltd. | 4.16% |
Zydus Lifesciences Ltd. | 3.10% |
Apollo Hospitals Enterprise Ltd. | 2.93% |
Biocon Ltd. | 2.39% |
Fund Manager
Name | Karan Doshi | Dharmesh Kakkad |
Start Date | 31 Jul 2023 | 23 Feb 2021 |
Name
Karan Doshi
Dharmesh Kakkad
Start Date
31 Jul 2023
23 Feb 2021
About Fund
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 08 Feb 2019 | 25 Jun 2018 |
Description
The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
08 Feb 2019
25 Jun 2018
